- Home
- Publications
- Publication Search
- Publication Details
Title
Protease inhibitor therapy for hepatitis C virus-infection
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 19, Issue 6, Pages 577-587
Publisher
Informa UK Limited
Online
2018-03-29
DOI
10.1080/14656566.2018.1454428
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV
- (2018) Chun-Jen Liu et al. GASTROENTEROLOGY
- Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
- (2018) J Bischoff et al. HIV MEDICINE
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
- (2018) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
- (2017) Ira M. Jacobson et al. GASTROENTEROLOGY
- Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure
- (2017) David Wyles et al. HEPATOLOGY
- Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis
- (2017) Guofeng Chen et al. HEPATOLOGY
- Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals
- (2017) Pamela S. Belperio et al. HEPATOLOGY
- HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study
- (2017) Karin Neukam et al. HIV CLINICAL TRIALS
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
- (2017) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- EASL Recommendations on Treatment of Hepatitis C 2016
- (2017) JOURNAL OF HEPATOLOGY
- Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
- (2017) Edward Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
- (2017) Marc Bourlière et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C virus NS3/4a protease inhibitors
- (2016) John A McCauley et al. CURRENT OPINION IN PHARMACOLOGY
- High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis
- (2016) Edward Gane et al. GASTROENTEROLOGY
- Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
- (2016) Paul Kwo et al. HEPATOLOGY
- Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)
- (2016) Eric Lawitz et al. HEPATOLOGY
- Hepatitis C genotype 3 disease
- (2016) Sarah Kattakuzhy et al. Hepatology International
- Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530
- (2016) T. Ng et al. JOURNAL OF HEPATOLOGY
- Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
- (2016) Jordan J. Feld et al. JOURNAL OF HEPATOLOGY
- Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The Hepnet Acute HCV IV Study
- (2016) K. Deterding et al. JOURNAL OF HEPATOLOGY
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
- (2016) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease
- (2016) Djadé I. Soumana et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study
- (2016) M. Rodriguez-Torres et al. JOURNAL OF VIRAL HEPATITIS
- Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
- (2016) Swathi Iyengar et al. PLOS MEDICINE
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
- (2015) Eric J. Lawitz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
- (2015) Preethi Krishnan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
- (2015) Christoph Sarrazin et al. ANTIVIRAL RESEARCH
- Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.
- (2015) Maria Buti et al. CLINICAL INFECTIOUS DISEASES
- Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
- (2015) Gregory J. Dore et al. GASTROENTEROLOGY
- G07 : The phase 3 C-EDGE treatment-naïve (TN) study of a 12-week oral regimen of grazoprevir (GZR, MK-5172)/ elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection
- (2015) S. Zeuzem et al. JOURNAL OF HEPATOLOGY
- P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial
- (2015) P. Kwo et al. JOURNAL OF HEPATOLOGY
- P0899 : Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857
- (2015) J.G. Taylor et al. JOURNAL OF HEPATOLOGY
- O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens
- (2015) P. Krishnan et al. JOURNAL OF HEPATOLOGY
- Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
- (2015) Oliver Lenz et al. JOURNAL OF HEPATOLOGY
- Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?
- (2015) Joop E. Arends et al. JOURNAL OF HEPATOLOGY
- Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
- (2015) Xavier Forns et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
- (2015) Mark Sulkowski et al. LANCET
- Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
- (2015) Julia Dietz et al. PLoS One
- Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment
- (2015) Jennifer Cohn et al. Current Opinion in HIV and AIDS
- Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
- (2015) Audrey Coilly et al. PLoS One
- In VitroandIn VivoAntiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
- (2014) Tami Pilot-Matias et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection
- (2014) Anita Y. M. Howe et al. CLINICAL INFECTIOUS DISEASES
- Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
- (2014) A. Hill et al. CLINICAL INFECTIOUS DISEASES
- Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
- (2014) Christophe Hézode et al. GUT
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
- (2014) Michael Manns et al. LANCET
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin
- (2014) John A. Howe et al. Open Forum Infectious Diseases
- Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a
- (2013) Navaneethan Palanisamy et al. ANTIVIRAL RESEARCH
- Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
- (2013) S. De Meyer et al. JOURNAL OF VIRAL HEPATITIS
- Ultrastructural analysis of hepatitis C virus particles
- (2013) Maria Teresa Catanese et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
- (2012) Fiona McPhee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C
- (2012) Claudio Pasquinelli et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
- (2012) Vincenzo Summa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study
- (2012) Christophe Moreno et al. JOURNAL OF HEPATOLOGY
- Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202)
- (2012) Oliver Lenz et al. JOURNAL OF HEPATOLOGY
- Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
- (2012) Doug J. Bartels et al. JOURNAL OF VIROLOGY
- The Burden of Liver Disease in Human Immunodeficiency Virus-Infected Patients
- (2012) Massimo Puoti et al. SEMINARS IN LIVER DISEASE
- NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1–5
- (2011) Sophie Vallet et al. ANTIVIRAL THERAPY
- Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors
- (2010) A. Bae et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Outcome of sustained virological responders with histologically advanced chronic hepatitis C
- (2010) Timothy R. Morgan et al. HEPATOLOGY
- Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
- (2009) Henk W. Reesink et al. GASTROENTEROLOGY
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
- (2009) John G. McHutchison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy
- (2008) Silvana Gaudieri et al. HEPATOLOGY
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
- (2008) Thomas Kuntzen et al. HEPATOLOGY
- Expert opinion on the treatment of patients with chronic hepatitis C
- (2008) S. Zeuzem et al. JOURNAL OF VIRAL HEPATITIS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now